NCT05948826View on ClinicalTrials.gov

First in Human Study of TORL-3-600 in Participants With Advanced Cancer

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

September 29, 2023

Primary Completion Date

June 25, 2026

Study Completion Date

September 15, 2026

Conditions
Advanced Solid TumorColorectal Cancer
Interventions
DRUG

TORL-3-600

antibody drug conjugate

Trial Locations (9)

37203

Sarah Cannon Research Institute-Tennessee, Nashville

46845

Fort Wayne Medical Oncology and Hematology Inc., Fort Wayne

63110

Washington University School of Medicine-Siteman Cancer Center, St Louis

75230

Mary Crowley Cancer Research, Dallas

80218

Sarah Cannon Research Institute, Denver

90095

UCLA - JCCC Clinical Research Unit, Los Angeles

92835

Providence Medical Foundation, Fullerton

M5G 2M9

University Health Network, Princess Margaret Cancer Centre, Toronto

H4A 3J1

McGill University Health Centre, Montreal

All Listed Sponsors
collaborator

Translational Research in Oncology

OTHER

lead

TORL Biotherapeutics, LLC

INDUSTRY

NCT05948826 - First in Human Study of TORL-3-600 in Participants With Advanced Cancer | Biotech Hunter | Biotech Hunter